Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Inavolisib vs Alpelisib in HR+/HER2-, PIK3CA-Mutated Advanced Breast Cancer (INAVO121)
NCT05646862Phase 3Recruiting
- Sponsor
- Roche
- Start
- Jun 2023
- Primary completion
- Nov 2026
- Modality
- Small Molecules
- Countries
- 20
01
Overview
A Phase 3 trial of inavolisib in breast cancer, sponsored by Roche. Started Jun 2023; status: recruiting.
02
Drugs
inavolisib
03
Conditions
breast cancer
Beyond the preview
Go deeper on NCT05646862.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05646862.